GOLD SPONSORS

PRTM Management Consultants, LLC draws upon deep biopharmaceutical industry experience to serve Government and Government-focused clients. PRTM uses best-in-class industry models paired with government-proven frameworks to bring new countermeasures from early technology development to commercial-scale production. PRTM's teams deliver objective, apolitical strategies to your toughest biodefense problems. We help you understand best-in-class practices from both the commercial and government sectors. During all of our client engagements, PRTM works to deliver strategic value that lasts long after our consultants have departed.

Chimerix, a biotechnology company located in Durham, NC was founded to develop orally available antiviral drugs to address unmet medical needs. Currently, drug development programs are underway for cytomegalovirus infection, genital warts (HPV) and drug resistant HIV infection. In 2003, the company began a biodefense program to develop an orally available smallpox drug which is partially funded by a $37.1M grant from the NIAID. The drug, CMX001, is currently in Phase I human trials, and is intended to provide a treatment option for individuals who are not good candidates for vaccination.

SILVER SPONSORS

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs to treat infection, cancer and inflammation. The Company's lead product candidate, cethromycin, is a second generation ketolide antibiotic in Phase III clinical development for the treatment of respiratory tract infections and for the prophylactic treatment of inhalation anthrax post-exposure under the FDA's Animal Rule.

DynPort Vaccine Company LLC, a CSC company, is a technology integrator providing solutions that protect humanity from emerging threats. DVC has comprehensive experience in the advanced development of biodefense biologics, including live attenuated vaccines, recombinant vaccines, therapeutics, therapeutic polyclonal antibodies and alternative vaccine delivery systems. The DVC pipeline includes botulinum polyclonal antibodies, butyrylcholinesterase ("BioScavenger"), and vaccines for plague, tularemia, botulinum neurotoxin and seasonal and pandemic influenza. We deliver results for our clients by engaging subcontractors, research centers and industry leaders. For more information, visit www.csc.com/dvc.

Emergent BioSolutions is a biopharmaceutical company focused on the development and manufacture of ImmunobioticsT - products that direct the body's immune system to treat and prevent life-threatening diseases. Founded as the world's only supplier of FDA-licensed anthrax vaccine, the company has a leading presence in the biodefense industry and a diversified prophylactic and therapeutic product portfolio. This portfolio includes a marketed product BioThrax®, six clinical stage and five preclinical stage anti-infective vaccines and immunotherapeutics.

Elusys Therapeutics, Inc. (Elusys) is a privately-held biopharmaceutical company focused on the development of targeted anti-infective drugs using proprietary Heteropoloymer (HP) Antibodies.

Elusys' HP Antibody technology has demonstrated a unique ability to clear and destroy pathogens and is a platform for the development of a deep pipeline of novel drug candidates targeted against bacterial, viral and fungal infections.

GenPhar, Inc. is a development-stage company with the mission to become a leading provider of biodefense and prophylactic/therapeutic vaccines for the world's most infectious viral diseases. GenPhar's advantage is its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple, multivalent vaccine products.

Implicit Bioscience Pty Ltd is an immunology-focused drug development company headquartered in Brisbane, Australia with its US office located in Seattle. Its veteran founders include Ian Frazer who discovered and developed the Gardasil vaccine for HPV and cervical cancer for Merck. Implicit's team is currently developing therapies for HCV and various bacterial biodefense agents.

McKenna Long & Aldridge LLP is a leader in the growing field of public health care and Biodefense procurement. We provide legal advice, government affairs counseling and venture capital consulting to pharmaceutical and biotech companies interested in securing contracts from the National Institutes of Health, Centers for Disease Control, Office of Health and Safety, Department of Defense and the Department of Health and Human Services. With approximately 350 lawyers and public policy advisors, we provide business solutions in the areas of corporate law, government contracts, intellectual property and technology, complex litigation, public policy and regulatory affairs, international law, real estate and finance. To learn more, log on to www.mckennalong.com.

PharmAthene was formed in March 2001 with a mission to become the premier company worldwide specializing in therapeutic and prophylactic products for defense against terrorist threats, with future expansion into broader commercial applications. PharmAthene is developing two lead biodefense products. In collaboration with Medarex, the company is developing ValortimTM, a human monoclonal antibody targeted against the anthrax toxin. In addition, PharmAthene is developing Protexia®, a recombinant human butyrylcholinesterase as a treatment for chemical for nerve agents.

BRONZE SPONSOR

Bridge is a preclinical CRO with facilities in Gaithersburg, Maryland and Beijing, China providing toxicology, pathology and bioanalytical services. Bridge conducts vaccine studies in our Maryland facility including Ebola, HIV, plague, West Nile, SARS, malaria.